GoldenGolden
Advanced Search
Orphazyme

Orphazyme

A biopharmaceutical company developing therapies to treat orphan protein-misfolding diseases

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

September 7, 2011
Orphazyme raises a $20,000,000 series A round from Aescap Venture.

Funding rounds

People

Name
Role
LinkedIn

Bernadette Vumbaca

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Vanessa Doctor, RN
June 29, 2021
BioSpace
Orphazyme said that its OLE trial, which has been running for the past 24 months, showed that arimoclomol could be an effective and safe option in treating Niemann-Pick disease type C.
Ben Adams
June 29, 2021
FierceBiotech
Orphazyme is taking the ax to most of its workforce after its beleaguered single asset has been hit by rejections and serial flops in the clinic.
Brandon May
June 18, 2021
BioSpace
The FDA said that the drug, which has been studied and submitted for NPC indication, needs further data to support its use in this rare, progressive genetic disorder.
Nick Paul
June 18, 2021
FierceBiotech
The FDA has rejected Orphazyme's Niemann-Pick disease type C drug candidate arimoclomol. Orphazyme said the agency wants additional data on the benefits and risks of the heat shock protein amplifier, leading it to cut costs as it figures out its next steps.
Mark Terry
June 14, 2021
BioSpace
The month of June continues to be busy for the U.S. Food and Drug Administration. There are three PDUFA dates on the calendar for this week. Here's a look.
Bloomberg
June 11, 2021
@bsindia
Orphazyme AS, which develops therapies to treat genetic disorders, says it has no idea why its American depositary shares surged overnight
Pomerantz LLP
May 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH). Such investors are...
Ben Adams
March 29, 2021
FierceBiotech
Orphazyme saw its stock sink more than 30% in Europe Monday morning after it failed to to hit any of the endpoints in a phase 2/3 trial.
November 11, 2020
BioSpace
CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C - read this article along with other careers information, tips and advice on BioSpace
BioSpace
May 26, 2020
BioSpace
CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the development of arimoclomol for the t
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.